Do you need a license to sell peptides in Vermont?

There is no standalone 'peptide license' issued by Vermont, and no single credential that authorizes a business to buy and resell peptides. What actually applies depends on which of three separate activities you are engaged in: operating a registered business at all, distributing anything that is legally classified as a drug or dispensed for human use, and buying or reselling research-use-only materials in a business-to-business context. Those three sit under different frameworks and different authorities, and the answer for your company depends on facts about your entity, your product classification, and your customer. This article is informational only and is not legal advice — the specifics belong to a Vermont-licensed attorney and the relevant state agencies.

The three questions hiding inside one

When an operator asks whether a license is needed, they are usually collapsing three distinct questions into one sentence.

The first is entity-level and mundane: is your business properly registered and in good standing, and do you hold whatever general registrations the state and your municipality require of any commercial seller? This is the same question a coffee roaster or a bookstore faces. It has nothing to do with peptides specifically, and it is the easiest of the three to resolve — usually through the Secretary of State's business filing process and your local clerk.

The second is product-classification: what, legally, is the thing you are selling? Frameworks governing wholesale drug distribution, pharmacy operations, prescribing, and dispensing are triggered by how a product is classified and how it is represented to the buyer — not by the word 'peptide.' A compound sold as a finished drug product for human use, a compound dispensed under a prescription, and a compound supplied to a laboratory for in-vitro research are three different legal postures, even if the underlying molecule is chemically identical.

The third is customer-facing and the one most operators underestimate: who is buying, and what are they buying it for? Selling to a business that is stocking a research catalog is a different transaction from supplying an individual for personal use, and the second scenario is where most operators create exposure they never intended.

The practical takeaway is that the honest answer to 'do I need a license' is another question: which lane are you actually in? Get that settled first, in writing, with counsel. Everything downstream — supplier selection, catalog scope, labeling, marketing copy — follows from it.

What research-use-only supply actually means for a business buyer

Research-use-only is not a marketing qualifier or a legal shield you paste onto a product page. It is a description of what the material is sold for: laboratory and research applications, not human or animal consumption, not administration, not clinical use. Compounds sold on that basis are not FDA-approved drugs, are not represented as treating or preventing anything, and carry no dosing, protocol, or administration guidance — because providing that guidance would contradict the classification itself.

For a business buyer, this has concrete operational consequences. Your product pages, your sales scripts, your customer service replies, and your email marketing all have to match the classification. A catalog that is labeled research-use-only but marketed with before-and-after language, suggested protocols, or human outcome claims is not really operating in the research lane — it is operating in the drug lane with a disclaimer attached, and a disclaimer does not reclassify anything.

It also shapes your customer qualification process. Businesses operating carefully in this space tend to build in some verification of who they are selling to and for what stated purpose, keep records of it, and decline orders that read like personal-use requests. None of that is a substitute for legal counsel, but it is the kind of operational discipline counsel will ask about.

The compounds themselves are studied for a wide range of mechanisms, and research suggests interest across areas like tissue signaling, metabolic pathways, and cellular repair. That research context is legitimate to discuss as science. It stops being legitimate the moment it is reframed as a promise to a person.

Questions to take to counsel and the state — not to a supplier

A supplier can tell you what it manufactures, how it tests, and how it ships. A supplier cannot tell you whether your specific business model is lawful in your specific state, and any supplier that confidently does should worry you. Here is how the questions divide.

Notice that a resale certificate appears on that list separately. Operators regularly assume a resale registration is the license, because it is the first peptide-adjacent piece of paper they obtain. It is a tax mechanism. It says nothing about whether the product category is one you are permitted to distribute.

Bring your actual plan to counsel, not a hypothetical. The answer changes materially depending on whether you are stocking a research catalog, operating a clinical business, or reselling online — and it can change again based on how your website describes the product.

If you operate a med spa, clinic, or telehealth business

Operators in these categories tend to arrive with a different version of the question: not 'can I sell' but 'can I add this.' That framing needs to be split apart too, because a clinical business has two entirely separate relationships with peptides. One is what it stocks and sells as products in a catalog. The other is anything involving a person — and that second one is governed by prescribing rules, scope-of-practice standards, professional board requirements, and the sourcing rules that apply to anything used clinically. Those are questions for the applicable board and your own attorney, and research-use-only supply does not answer them, because research-use-only material is not supplied for that purpose in the first place.

What a wholesale research supply relationship does support is the business side: stocking your shelves, building a research catalog under your own brand, serving business customers, and adding a product line with predictable sourcing and documentation behind it. Real Peptides' wholesale peptides program is built for that use case — med spas, clinics, wellness businesses, telehealth companies, and resellers who need consistent supply and paperwork they can show.

One boundary worth stating plainly: Real Peptides does not offer semaglutide, tirzepatide, retatrutide, or melanotan through its wholesale program. If a supplier is offering you those compounds alongside a research-use-only catalog, that is a signal about how seriously they take the classification question — and about what their compliance posture will look like when a regulator asks.

How to vet a wholesale supplier before you commit

Once the legal lane is settled, supplier diligence is the next real decision, and it is one you control entirely. The peptide wholesale market contains excellent operators and opaque ones, and the difference usually shows up before you place a first order.

The COA question is the one that separates suppliers fastest. Analytical documentation only means something if it corresponds to the batch in your hand and if you can retrieve it yourself. A COA you have to request, pay for, or take on faith is a marketing asset, not a quality control record.

What Real Peptides does differently

Real Peptides supplies research-use-only compounds to business buyers and publishes the evidence behind them rather than describing it. Purity is verified at 99%+ by HPLC. Batches go through multi-point testing covering identity, purity, and contamination panels, and the resulting COAs are publicly verifiable — the reader can check the lab results directly rather than requesting them, and rather than paying for them as an extra.

Pricing tiers are disclosed during the application process instead of held back for a negotiation. Orders are fulfilled from within the United States, and the published fulfillment window appears on the wholesale program page — confirm current timing when you apply, since logistics conditions change.

The application itself is three steps: submit business details, get reviewed and approved as a wholesale account, then place orders against your tier. The review exists because knowing who your buyers are is part of operating responsibly in this category, not an obstacle to it. Approved partners can build across the catalog, including widely stocked options in the popular peptides collection, and all of it stays research use only, with no human-use kits, no bundled supplies implying administration, and no protocol guidance.

Where to go from here

If you have your entity registration in order and you have had the classification conversation with your own attorney, the remaining step is supply. Businesses that have settled their legal footing and want documented, tested, domestically fulfilled research compounds can apply for a wholesale account and see tier pricing during review.

For more on how licensing frameworks intersect with research-use-only supply across jurisdictions, see the broader overview of do you need a license to sell peptides, the details of the wholesale peptides program, or go straight to the application to apply for a wholesale account.